US3941763A
(en)
|
1975-03-28 |
1976-03-02 |
American Home Products Corporation |
PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
|
US4704362A
(en)
|
1977-11-08 |
1987-11-03 |
Genentech, Inc. |
Recombinant cloning vehicle microbial polypeptide expression
|
US4215051A
(en)
|
1979-08-29 |
1980-07-29 |
Standard Oil Company (Indiana) |
Formation, purification and recovery of phthalic anhydride
|
US4456591A
(en)
|
1981-06-25 |
1984-06-26 |
Baxter Travenol Laboratories, Inc. |
Therapeutic method for activating factor VII
|
AU561343B2
(en)
|
1981-10-19 |
1987-05-07 |
Genentech Inc. |
Human immune interferon by recombinant dna
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US6936694B1
(en)
|
1982-05-06 |
2005-08-30 |
Intermune, Inc. |
Manufacture and expression of large structural genes
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
US4694778A
(en)
|
1984-05-04 |
1987-09-22 |
Anicon, Inc. |
Chemical vapor deposition wafer boat
|
US5189015A
(en)
|
1984-05-30 |
1993-02-23 |
Alfa-Laval Agri International Ab |
Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
|
US5077204A
(en)
|
1984-06-21 |
1991-12-31 |
Chiron Corporation |
Yeast endopeptidase for basic amino-acid site cleavage, preparation and use
|
US4766073A
(en)
|
1985-02-25 |
1988-08-23 |
Zymogenetics Inc. |
Expression of biologically active PDGF analogs in eucaryotic cells
|
US4889919A
(en)
|
1986-08-13 |
1989-12-26 |
Zymogenetics, Inc. |
Biologically active PDGF derived A-chain homodimers
|
DK525384D0
(da)
|
1984-11-05 |
1984-11-05 |
Nordisk Insulinlab |
Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
|
US5157021A
(en)
|
1985-03-15 |
1992-10-20 |
Novo Nordisk A/S |
Insulin derivatives and pharmaceutical preparations containing these derivatives
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
AU5772886A
(en)
|
1985-04-12 |
1986-11-05 |
Genetics Institute Inc. |
Novel procoagulant proteins
|
GR860984B
(en)
|
1985-04-17 |
1986-08-18 |
Zymogenetics Inc |
Expression of factor vii and ix activities in mammalian cells
|
US4745055A
(en)
|
1985-05-07 |
1988-05-17 |
California Biotechnology Inc. |
Fused protein for enzyme immunoassay system
|
KR910006424B1
(ko)
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
편성브리프(brief) 제조방법
|
US5180583A
(en)
|
1985-11-26 |
1993-01-19 |
Hedner Ulla K E |
Method for the treatment of bleeding disorders
|
EP0253870B1
(en)
|
1986-01-03 |
1993-03-31 |
Genetics Institute, Inc. |
Method for producing factor viii:c-type proteins
|
US4786726A
(en)
|
1986-01-06 |
1988-11-22 |
Blood Systems, Inc. |
Factor IX therapeutic blood product, means and methods of preparing same
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
US5543502A
(en)
|
1986-06-24 |
1996-08-06 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
EP0832981A1
(en)
|
1987-02-17 |
1998-04-01 |
Pharming B.V. |
DNA sequences to target proteins to the mammary gland for efficient secretion
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
IL86693A
(en)
|
1987-06-12 |
1994-06-24 |
Stichting Centraal Lab |
Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US5892019A
(en)
|
1987-07-15 |
1999-04-06 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Production of a single-gene-encoded immunoglobulin
|
FR2619314B1
(fr)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
US5234830A
(en)
|
1988-02-03 |
1993-08-10 |
Suntory Limited |
DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
|
JP2643968B2
(ja)
|
1988-02-03 |
1997-08-25 |
サントリー株式会社 |
Kex2エンドプロテアーゼ及びその製造方法
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
US5750373A
(en)
|
1990-12-03 |
1998-05-12 |
Genentech, Inc. |
Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
|
WO1990005183A1
(en)
|
1988-10-31 |
1990-05-17 |
Immunex Corporation |
Interleukin-4 receptors
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
CA2053864C
(en)
|
1989-02-21 |
2001-11-20 |
Irving Boime |
Modified forms of reproductive hormones
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US5766883A
(en)
|
1989-04-29 |
1998-06-16 |
Delta Biotechnology Limited |
Polypeptides
|
SE8901687D0
(sv)
|
1989-05-11 |
1989-05-11 |
Alfa Laval Agri Int |
Fibronectin binding protein as well as its preparation
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
US5194596A
(en)
|
1989-07-27 |
1993-03-16 |
California Biotechnology Inc. |
Production of vascular endothelial cell growth factor
|
US5395760A
(en)
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
ATE236249T1
(de)
|
1989-09-12 |
2003-04-15 |
Hoffmann La Roche |
Tfn-bindende proteine
|
US5935815A
(en)
|
1989-10-25 |
1999-08-10 |
Katholieke Universiteit Leuven |
Process for micro biological production of proteins
|
US5633076A
(en)
|
1989-12-01 |
1997-05-27 |
Pharming Bv |
Method of producing a transgenic bovine or transgenic bovine embryo
|
SE465222C5
(sv)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
US5648273A
(en)
|
1989-12-27 |
1997-07-15 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Hepatic growth factor receptor is the MET proto-oncogene
|
SG48759A1
(en)
|
1990-01-12 |
2002-07-23 |
Abgenix Inc |
Generation of xenogenic antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
GB9009106D0
(en)
|
1990-04-23 |
1990-06-20 |
3I Res Expl Ltd |
Processes and intermediates for synthetic antibody derivatives
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5453491A
(en)
|
1990-09-11 |
1995-09-26 |
Kiyoshi Takatsu |
Murine interleukin-5 receptor
|
EP0785273A1
(en)
|
1990-11-26 |
1997-07-23 |
Genetics Institute, Inc. |
Paired basic amino acid converting enzyme and DNA sequence encoding it
|
DK0517895T3
(da)
|
1990-12-14 |
1997-04-07 |
Univ California |
Kimæriske kæder til receptorforbundne signaltransduktionsveje
|
GEP20033082B
(en)
|
1991-03-15 |
2003-10-27 |
Amgen Inc |
Pegylation of Polypeptides
|
US5374617A
(en)
|
1992-05-13 |
1994-12-20 |
Oklahoma Medical Research Foundation |
Treatment of bleeding with modified tissue factor in combination with FVIIa
|
WO1992018628A1
(en)
|
1991-04-19 |
1992-10-29 |
Schering Corporation |
Subunit of the human interleukin-3 receptor
|
DK0636173T3
(da)
|
1991-05-31 |
1999-05-31 |
Genentech Inc |
Behandling af HIV associeret immunthrombocytopenisk purpura
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
US5227158A
(en)
|
1991-06-10 |
1993-07-13 |
Genentech, Inc. |
Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
|
US5346991A
(en)
|
1991-06-13 |
1994-09-13 |
Genentech, Inc. |
Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
US5116753A
(en)
|
1991-07-30 |
1992-05-26 |
The Salk Institute For Biological Studies |
Maintenance of pancreatic islets
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
RU2128709C1
(ru)
|
1992-01-23 |
1999-04-10 |
Мерк Патент Гмбх |
Способ получения димерного одноцепочечного слитого белка (варианты)
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
CA2128862C
(en)
|
1992-02-11 |
2008-05-20 |
Jonathan G. Seidman |
Homogenotization of gene-targeting events
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
US6037452A
(en)
|
1992-04-10 |
2000-03-14 |
Alpha Therapeutic Corporation |
Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
|
WO1993024135A1
(en)
|
1992-05-26 |
1993-12-09 |
Immunex Corporation |
Novel cytokine that binds cd30
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
ATE198277T1
(de)
|
1992-10-02 |
2001-01-15 |
Genetics Inst |
Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
|
US6277975B1
(en)
|
1992-10-23 |
2001-08-21 |
Genetics Institute, Inc. |
Fusions of P-selectin ligand protein and polynucleotides encoding same
|
CA2149326C
(en)
|
1992-11-13 |
2007-04-17 |
Mitchell E. Reff |
Fully impaired consensus kozak sequences for mammalian expression
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
WO1994028017A1
(en)
|
1993-06-01 |
1994-12-08 |
The Scripps Research Institute |
Human mutant tissue factor compositions useful as tissue factor antagonists
|
US6479055B1
(en)
|
1993-06-07 |
2002-11-12 |
Trimeris, Inc. |
Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
|
US6518013B1
(en)
|
1993-06-07 |
2003-02-11 |
Trimeris, Inc. |
Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
|
US5464933A
(en)
|
1993-06-07 |
1995-11-07 |
Duke University |
Synthetic peptide inhibitors of HIV transmission
|
US6017536A
(en)
|
1993-06-07 |
2000-01-25 |
Trimeris, Inc. |
Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
|
US5621039A
(en)
|
1993-06-08 |
1997-04-15 |
Hallahan; Terrence W. |
Factor IX- polymeric conjugates
|
US6310180B1
(en)
|
1993-06-21 |
2001-10-30 |
Vanderbilt University |
Method for synthesis of proteins
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US6740734B1
(en)
|
1994-01-14 |
2004-05-25 |
Biovitrum Ab |
Bacterial receptor structures
|
DE69521789T2
(de)
|
1994-02-01 |
2002-04-25 |
Us Health |
Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
|
DE4405426A1
(de)
|
1994-02-21 |
1995-08-24 |
Boehringer Mannheim Gmbh |
Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US6372716B1
(en)
|
1994-04-26 |
2002-04-16 |
Genetics Institute, Inc. |
Formulations for factor IX
|
US5648240A
(en)
|
1994-05-24 |
1997-07-15 |
Texas A&M University |
MHC II analog from Staphylococcus aureus
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
US5596080A
(en)
|
1994-10-03 |
1997-01-21 |
E. I. Du Pont De Nemours And Company |
Crosslinking processes/agents for zein
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5591573A
(en)
|
1995-04-10 |
1997-01-07 |
Alpha Therapeutic Corporation |
Method and system for testing blood samples
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5579277A
(en)
|
1995-05-01 |
1996-11-26 |
Apple Computer, Inc. |
System and method for interleaving memory banks
|
US6184344B1
(en)
|
1995-05-04 |
2001-02-06 |
The Scripps Research Institute |
Synthesis of proteins by native chemical ligation
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
CA2224008C
(en)
|
1995-06-07 |
2009-08-18 |
Trimeris, Inc. |
The treatment of hiv and other viral infections using combinatorial therapy
|
US5811524A
(en)
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US5840529A
(en)
|
1995-08-02 |
1998-11-24 |
Clinical Research Institute Of Montreal |
Mammalian pro-hormone convertase
|
DK0848755T4
(da)
|
1995-09-08 |
2011-05-23 |
Genentech Inc |
VEGF relateret protein
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
US5770700A
(en)
|
1996-01-25 |
1998-06-23 |
Genetics Institute, Inc. |
Liquid factor IX formulations
|
CA2198968C
(en)
|
1996-03-04 |
2010-02-09 |
Toyofumi Masuda |
Process for production of secretory kex2 derivatives
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
JP2000515735A
(ja)
|
1996-07-03 |
2000-11-28 |
ジェネンテック インコーポレーテッド |
肝細胞成長因子レセプターアゴニスト
|
CA2203745A1
(en)
|
1996-07-26 |
1998-01-26 |
Robert Day |
Pro-protein converting enzyme
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
US6159462A
(en)
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
ZA977959B
(en)
*
|
1996-10-16 |
1998-03-23 |
Alza Corp |
Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity.
|
IN184589B
(es)
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
EP2371962A3
(en)
|
1996-12-23 |
2011-12-21 |
Immunex Corporation |
Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
|
US6271349B1
(en)
|
1996-12-23 |
2001-08-07 |
Immunex Corporation |
Receptor activator of NF-κB
|
TW502011B
(en)
|
1997-02-05 |
2002-09-11 |
Ajinomoto Kk |
Process for producing n-long-chain acyl acidic amino acids or salts thereof
|
AU735463B2
(en)
|
1997-02-14 |
2001-07-12 |
American Red Cross |
Expression of active human factor IX in mammary tissue of transgenic animals
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
CA2225189C
(en)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Canine factor viii gene, protein and methods of use
|
ATE296356T1
(de)
|
1997-03-14 |
2005-06-15 |
Biogen Idec Inc |
Methode zur spezifischen integration von genen in säugetierzellen durch homologe rekombination, und vektoren zu deren durchführung
|
US6673901B2
(en)
|
1997-06-12 |
2004-01-06 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
US6326468B1
(en)
|
1997-06-13 |
2001-12-04 |
Gryphon Sciences |
Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
|
US6310183B1
(en)
|
1997-09-10 |
2001-10-30 |
Novo Nordisk A/S |
Coagulation factor VIIa composition
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
US6008321A
(en)
|
1998-03-16 |
1999-12-28 |
Pharmacopeia, Inc. |
Universal linker for combinatorial synthesis
|
US6281331B1
(en)
|
1998-03-23 |
2001-08-28 |
Trimeris, Inc. |
Methods and compositions for peptide synthesis
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
AU3871099A
(en)
|
1998-05-06 |
1999-11-23 |
Temple University - Of The Commonwealth System Of Higher Education |
Reversal of proinflammatory response by ligating the macrophage fcgammari receptor
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6355782B1
(en)
|
1998-07-09 |
2002-03-12 |
Baylor College Of Medicine |
Hypohidrotic ectodermal dyplasia genes and proteins
|
AU766970B2
(en)
|
1998-07-15 |
2003-10-30 |
Genentech Inc. |
Tissue factor protein variants with increased affinity for coagulation factor FVII/FVIIa
|
CN1309770A
(zh)
|
1998-07-31 |
2001-08-22 |
华莱士·E·卡罗尔 |
确定抗凝治疗因子的设备和方法
|
US20020142374A1
(en)
|
1998-08-17 |
2002-10-03 |
Michael Gallo |
Generation of modified molecules with increased serum half-lives
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
ES2315022T3
(es)
|
1998-11-06 |
2009-03-16 |
Novo Nordisk Health Care Ag |
Metodo para la produccion de fvii.
|
US6280994B1
(en)
|
1998-11-25 |
2001-08-28 |
Zymogenetics, Inc. |
Zace 1: a human metalloenzyme
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
JP3971108B2
(ja)
|
1999-01-06 |
2007-09-05 |
ジェネンテック・インコーポレーテッド |
インシュリン様成長因子(igf)i突然変異体
|
PT1141015E
(pt)
|
1999-01-06 |
2009-10-13 |
Genentech Inc |
Variantes mutantes do factor de crescimento do tipo insulina (igf)i
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6602977B1
(en)
|
1999-04-19 |
2003-08-05 |
Biovitrum Ab |
Receptor structures
|
AU781618C
(en)
|
1999-07-02 |
2006-03-16 |
Genentech Inc. |
FVIIa antagonists
|
US6469136B1
(en)
|
1999-07-07 |
2002-10-22 |
Trimeris, Inc. |
Methods and composition for peptide synthesis
|
JP2001151694A
(ja)
|
1999-09-17 |
2001-06-05 |
Takeda Chem Ind Ltd |
タンパク質粉体の製造法
|
DE19963859A1
(de)
|
1999-12-30 |
2001-07-12 |
Apotech Res & Dev Ltd |
Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
|
DK1252192T3
(da)
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
|
JP2003531590A
(ja)
|
2000-04-12 |
2003-10-28 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
CN1214039C
(zh)
|
2000-04-28 |
2005-08-10 |
茵弗莱采姆药物有限公司 |
3-氮-6,7-二氧甾族化合物及其应用
|
ATE448301T1
(de)
|
2000-09-08 |
2009-11-15 |
Univ Zuerich |
Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
|
US7138119B2
(en)
|
2000-09-15 |
2006-11-21 |
Progenics Pharmaceuticals, Inc. |
Compositions and methods for inhibition of HIV-1 infection
|
WO2002055110A2
(en)
|
2000-10-25 |
2002-07-18 |
Genzyme Corp |
Methods for treating blood coagulation disorders
|
WO2002040544A2
(en)
|
2000-11-14 |
2002-05-23 |
Board Of Regents, University Of Texas Systems |
Mutant human factor ix with an increased resistance to inhibition by heparin
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
CA2431600C
(en)
|
2000-12-12 |
2012-04-17 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
US20030203845A1
(en)
|
2001-02-05 |
2003-10-30 |
Knudsen Jens Bjerre |
Combined use of factor VII polypeptides and factor IX polypeptides
|
US7419949B2
(en)
|
2001-07-16 |
2008-09-02 |
Novo Noridsk Healthcare A/G |
Single-dose administration of factor VIIa
|
PL369065A1
(en)
|
2001-09-04 |
2005-04-18 |
Merck Patent Gmbh |
Modified factor ix
|
ES2288900T3
(es)
|
2001-10-05 |
2008-02-01 |
Affimed Therapeutics Ag |
Anticuerpo de origen humano para inhibir la agregacion de trombocitos.
|
FR2831170B1
(fr)
|
2001-10-19 |
2004-03-19 |
Inst Nat Sante Rech Med |
Proteines c modifiees activables directement par la thrombine
|
US20030078180A1
(en)
|
2001-10-24 |
2003-04-24 |
Benchmark Research & Technology, Inc. |
Contaminant-tolerant foaming additive
|
KR101271635B1
(ko)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
EP1997829A1
(en)
|
2001-12-21 |
2008-12-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
EP1487879B1
(en)
|
2002-03-01 |
2012-12-26 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
WO2003077834A2
(en)
|
2002-03-15 |
2003-09-25 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
EP2298805A3
(en)
|
2002-09-27 |
2011-04-13 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
CA2502904C
(en)
|
2002-10-15 |
2013-05-28 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
ES2911435T3
(es)
|
2003-02-26 |
2022-05-19 |
Nektar Therapeutics |
Conjugados de polímero-resto de Factor VIII
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
EP3552627A1
(en)
|
2003-05-06 |
2019-10-16 |
Bioverativ Therapeutics Inc. |
Clotting factor-fc chimeric proteins to treat hemophilia
|
AU2004238263A1
(en)
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
WO2004108885A2
(en)
|
2003-05-06 |
2004-12-16 |
Syntonix Pharmaceuticals, Inc. |
Fc chimeric proteins with anti-hiv drugs
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
US7212798B1
(en)
|
2003-07-17 |
2007-05-01 |
Cisco Technology, Inc. |
Adaptive AGC in a wireless network receiver
|
JP2005060378A
(ja)
|
2003-07-28 |
2005-03-10 |
Yamanouchi Pharmaceut Co Ltd |
生理活性蛋白質含有凍結乾燥製剤
|
US20050152979A1
(en)
|
2003-09-05 |
2005-07-14 |
Cell Therapeutics, Inc. |
Hydrophobic drug compositions containing reconstitution enhancer
|
EP1673395A1
(en)
|
2003-10-15 |
2006-06-28 |
PDL BioPharma, Inc. |
Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
KR100775343B1
(ko)
|
2003-11-13 |
2007-11-08 |
한미약품 주식회사 |
면역글로불린 Fc 영역을 캐리어로 포함하는 약제학적조성물
|
US8263084B2
(en)
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
EP1684790A4
(en)
|
2003-11-18 |
2008-04-30 |
Iconic Therapeutics Inc |
HOMOGENEOUS PREPARATIONS OF CHIMERIC PROTEINS
|
RU2373953C2
(ru)
|
2003-12-19 |
2009-11-27 |
Ново Нордиск Хелс Кеа Аг |
Стабилизированная композиция, содержащая полипептид фактора vii
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
CN1918178B
(zh)
|
2004-01-12 |
2012-08-22 |
应用分子进化公司 |
Fc区变体
|
WO2005089712A1
(en)
|
2004-03-04 |
2005-09-29 |
Wyeth |
Lyophilization method to improve excipient crystallization
|
WO2005092925A2
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
CN105753968A
(zh)
|
2004-11-12 |
2016-07-13 |
拜尔健康护理有限责任公司 |
Fviii的位点定向修饰
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
WO2006055689A2
(en)
|
2004-11-16 |
2006-05-26 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
SI1827483T1
(sl)
|
2004-12-15 |
2014-11-28 |
Swedish Orphan Biovitrum Ab (Publ) |
Terapevtske formulacije keratinocitnega rastnega faktorja
|
US20060162552A1
(en)
|
2005-01-26 |
2006-07-27 |
Mohawk Valley Energy Solutions, Inc. |
Systems and methods for controlling room air quality
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
US7956160B2
(en)
|
2005-07-22 |
2011-06-07 |
Amgen Inc. |
Concentrated protein lyophilates, methods, and uses
|
WO2007021494A2
(en)
|
2005-08-12 |
2007-02-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
US7666622B2
(en)
|
2005-10-19 |
2010-02-23 |
Regeneron Pharmaceuticals, Inc. |
Monomeric self-associating fusion polypeptides and therapeutic uses thereof
|
PT3225233T
(pt)
|
2005-11-01 |
2019-10-24 |
Wyeth Llc |
Solução de cloreto de sódio para reconstituição de fármacos.
|
US8759292B2
(en)
|
2006-02-03 |
2014-06-24 |
Prolor Biotech, Llc |
Long-acting coagulation factors and methods of producing same
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
EP1820508A1
(en)
|
2006-02-21 |
2007-08-22 |
CSL Behring GmbH |
Coagulation factor X polypeptides with modified activation properties
|
WO2007103455A2
(en)
|
2006-03-06 |
2007-09-13 |
Amunix, Inc. |
Genetic packages and uses thereof
|
SG170750A1
(en)
|
2006-03-17 |
2011-05-30 |
Biogen Idec Inc |
Stabilized polypeptide compositions
|
LT2004683T
(lt)
|
2006-03-24 |
2016-10-10 |
Biogen Hemophilia Inc. |
Pc5, kaip faktoriaus ix pro-peptidą apdorojantis fermentas
|
BRPI0709737A2
(pt)
|
2006-04-04 |
2011-07-26 |
Zymenex As |
processo para concentraÇço de um polipeptÍdeo
|
US20100222554A1
(en)
|
2006-04-11 |
2010-09-02 |
Thomas Weimer |
Method of Increasing the In Vivo Recovery of Therapeutic Polypeptides
|
WO2007135182A2
(en)
|
2006-05-24 |
2007-11-29 |
Novo Nordisk Health Care Ag |
Factor ix analogues having prolonged in vivo half life
|
US7939632B2
(en)
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
WO2007144173A1
(en)
|
2006-06-14 |
2007-12-21 |
Csl Behring Gmbh |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
EP2084274A2
(en)
|
2006-06-19 |
2009-08-05 |
Nautilus Technology LLC |
Modified coagulation factor ix polypeptides and use thereof for treatment
|
WO2008022151A1
(en)
|
2006-08-15 |
2008-02-21 |
Inspiration Biopharmaceuticals, Inc. |
Prophylactic treatment of hemophilia
|
US8015841B2
(en)
|
2006-09-08 |
2011-09-13 |
Praxair Technology, Inc. |
Cryogenic refrigeration system for lyophilization
|
WO2008033413A2
(en)
|
2006-09-14 |
2008-03-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7700734B2
(en)
|
2007-01-09 |
2010-04-20 |
Shu-Wha Lin |
Recombinant human factor IX and use thereof
|
WO2008131242A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
KR101631323B1
(ko)
|
2007-06-21 |
2016-06-17 |
엑스엘-프로테인 게엠베하 |
증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질
|
MX2010001684A
(es)
|
2007-08-15 |
2010-04-21 |
Amunix Inc |
Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
|
CA2702363A1
(en)
|
2007-10-15 |
2009-04-23 |
The University Of North Carolina At Chapel Hill |
Human factor ix variants with an extended half life
|
CA2991162A1
(en)
*
|
2007-12-21 |
2009-07-02 |
Aptevo Biotherapeutics Llc |
Stabilized factor ix formulations containing trehalose
|
CN101952422A
(zh)
|
2007-12-27 |
2011-01-19 |
巴克斯特国际公司 |
化学修饰的因子ix
|
TWI538916B
(zh)
|
2008-04-11 |
2016-06-21 |
介控生化科技公司 |
經修飾的因子vii多肽和其用途
|
RU2010146387A
(ru)
|
2008-04-16 |
2012-05-27 |
БАЙЕР ХЕЛСКЕР ЛЛСи (US) |
Модифицированные полипептиды фактора ix и их применение
|
CA2721362A1
(en)
|
2008-04-16 |
2009-11-19 |
Bayer Healthcare Llc |
Site-directed modification of factor ix
|
JP5665733B2
(ja)
|
2008-04-21 |
2015-02-04 |
ノボ ノルディスク ヘルス ケア アーゲー |
高度にグリコシル化されたヒト凝固第ix因子
|
DK2280734T3
(da)
|
2008-04-24 |
2014-05-26 |
Cantab Biopharmaceuticals Patents Ltd |
Faktor-ix-konjugater med forlængede halveringstider
|
EP3572073B1
(en)
|
2008-08-05 |
2023-12-20 |
Wyeth LLC |
Lyophilization above collapse
|
CA2732423A1
(en)
|
2008-08-21 |
2010-02-25 |
Octapharma Ag |
Recombinantly produced human factor viii and ix
|
AU2009295623A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Stabilitech Ltd |
Method for preserving polypeptides using a sugar and polyethyleneimine
|
WO2010091122A1
(en)
|
2009-02-03 |
2010-08-12 |
Amunix, Inc. |
Extended recombinant polypeptides and compositions comprising same
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
US9493545B2
(en)
|
2009-02-11 |
2016-11-15 |
Albumedix A/S |
Albumin variants and conjugates
|
CN102482340B
(zh)
|
2009-04-06 |
2015-05-13 |
诺沃—诺迪斯克有限公司 |
因子viii蛋白向血小板的靶向递送
|
CN106916229A
(zh)
|
2009-06-08 |
2017-07-04 |
阿穆尼克斯运营公司 |
生长激素多肽及其制备和使用方法
|
WO2010144508A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
KR20120027031A
(ko)
|
2009-06-18 |
2012-03-20 |
와이어쓰 엘엘씨 |
소형 모듈 면역제약용 동결건조 제제
|
CA2764758C
(en)
|
2009-06-25 |
2019-02-12 |
The University Of North Carolina At Chapel Hill |
Chimeric factor vii molecules
|
WO2011017070A1
(en)
|
2009-07-28 |
2011-02-10 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
WO2011028228A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
CN102574908B
(zh)
|
2009-08-27 |
2018-08-03 |
诺沃—诺迪斯克有限公司 |
组织因子向活化的血小板的靶向
|
JP2013509170A
(ja)
|
2009-10-30 |
2013-03-14 |
ノボザイムス バイオファーマ デーコー アクティーゼルスカブ |
アルブミン変異体
|
EP2353588B1
(en)
|
2010-01-21 |
2015-04-15 |
Agricultural Technology Research Institute |
A sustained release preparation of factor IX
|
JP2013520480A
(ja)
*
|
2010-02-24 |
2013-06-06 |
アレコー リミテッド |
第ix因子の安定組成物
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
SI2591006T1
(sl)
|
2010-07-09 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo
|
EP2590668A4
(en)
|
2010-07-09 |
2014-04-02 |
Biogen Idec Hemophilia Inc |
FACTOR IX POLYPEPTIDES AND METHOD OF USE THEREOF
|
SG188662A1
(en)
|
2010-09-30 |
2013-05-31 |
Toyama Chemical Co Ltd |
Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
|
RU2650784C2
(ru)
|
2011-05-05 |
2018-04-17 |
Альбумедикс А/С |
Варианты альбумина
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
WO2013106787A1
(en)
|
2012-01-12 |
2013-07-18 |
Biogen Idec Ma Inc. |
Chimeric factor viii polypeptides and uses thereof
|
LT2802668T
(lt)
|
2012-01-12 |
2018-11-26 |
Bioverativ Therapeutics Inc. |
Imunogeninio atsako prieš faktorių viii individuose, kuriems skiriama faktoriaus viii terapija, sumažinimas
|
RS59833B1
(sr)
|
2012-02-15 |
2020-02-28 |
Bioverativ Therapeutics Inc |
Sastavi faktora viii i postupci za pravljenje i upotrebu istih
|
EP3693000B1
(en)
|
2012-06-08 |
2022-03-02 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
WO2014011819A2
(en)
|
2012-07-11 |
2014-01-16 |
Amunix Operating Inc. |
Factor viii complex with xten and von willebrand factor protein, and uses thereof
|
WO2014052490A1
(en)
*
|
2012-09-25 |
2014-04-03 |
Biogen Idec Ma Inc. |
Methods of using fix polypeptides
|
EP2914293A4
(en)
|
2012-10-30 |
2016-04-20 |
Biogen Ma Inc |
METHOD OF USE OF FVIII POLYPEPTIDE
|
CN105007722A
(zh)
|
2013-02-16 |
2015-10-28 |
诺维信生物制药丹麦公司 |
药代动力学动物模型
|
PL3666283T3
(pl)
|
2013-03-15 |
2022-10-03 |
Bioverativ Therapeutics Inc. |
Formulacje polipeptydu czynnika viii
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
AU2015204646B2
(en)
|
2014-01-10 |
2020-08-27 |
Bioverativ Therapeutics Inc. |
Factor VIII chimeric proteins and uses thereof
|
SG11201607642RA
(en)
*
|
2014-03-24 |
2016-10-28 |
Biogen Ma Inc |
Lyophilized factor ix formulations
|
IL266972B2
(en)
|
2016-12-02 |
2024-04-01 |
Bioverativ Therapeutics Inc |
Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
|
WO2018102760A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|